Clinical trial

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

NCT04028388

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-07-17

PhasePHASE2

Study timeline

Study start (actual)2019-07-17Date precision: day

Registry last updated2024-04-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancer Metastaticunresolved

Castration-resistant Prostate Cancerunresolved

Interventions

Docetaxel in Parenteral Dosage FormDRUG

ModraDoc006/rDRUG

Sponsors & collaborators

Modra Pharmaceuticalslead sponsor

Mapped research locations

Saint PetersburgRussia4 PortlandOregon, United States1 DetroitMichigan, United States1 Las VegasNevada, United States1 MoscowRussia1 WarsawPoland1 BudapestHungary1 PragueCzechia1 LodzPoland1 DebrecenHungary1 NovosibirskRussia1 TübingenGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04028388 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.